Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00350636 · ClinicalTrials.gov registry record · Phase 3
A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo
A Phase 3 study, sponsored by Watson Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 789
- Enrollment target
NCT00350636: Completed Phase 3 study, sponsored by Watson Pharmaceuticals.
NCT00350636 is a Phase 3 study that has completed, run by Watson Pharmaceuticals. The registered enrollment target is 789 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00350636, a Phase 3 study, has completed, sponsored by Watson Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 789 participants
- Enrollment target
Study Summary
A new drug for overactive bladder is compared to placebo to determine if it is safe and effective. The study lasts approximately 12 weeks.
Primary Outcome
Average number of daily incontinence episodes at baseline
Interventions
- DRUG Oxybutynin topical gel
- OTHER Placebo topical gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 789 participants |
| Start Date | 2006-06 |
| Est. Completion | 2007-05 |
| Phase | Phase 3 |
What the finished NCT00350636 record still lists
NCT00350636 is an interventional study that assigns participants to a tested intervention. The registered 789 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Oxybutynin topical gel is the first listed.
NCT00350636 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00350636 about?
NCT00350636 is a clinical study titled "A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo". A new drug for overactive bladder is compared to placebo to determine if it is safe and effective. The study lasts approximately 12 weeks.
What is the current status of trial NCT00350636?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 789 participants. The study started on 2006-06. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00350636?
The interventions under investigation include: Oxybutynin topical gel (DRUG), Placebo topical gel (OTHER).
Who is sponsoring clinical trial NCT00350636?
This trial is sponsored by Watson Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00350636's enrollment target sits among peer trials
789 431st of 2000 higher than 1,570 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04967989 · 790 participants · Phase 3
Clarifying the Optimal Application of SLT Therapy Trial
- NCT06162611 · 790 participants · Phase 4
Etonogestrel (ENG) Implant Insertion for Emergency Contraception With Oral Levonorgestrel (LNG) vs Placebo
- NCT06488781 · 787 participants · Phase 2
Antibiotic Prophylaxis to Prevent Obesity-Related Induction Complications in Nulliparae at Term 2.0
- NCT06876649 · 787 participants · Phase 4
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia